Compugen Ltd.
$2.88
▲
2.73%
2026-04-21 06:00:01
cgen.com
NCM: CGEN
Explore Compugen Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$269 M
Current Price
$2.88
52W High / Low
$2.94 / $1.23
Stock P/E
7.61
Book Value
$1.09
Dividend Yield
—
ROCE
23.38%
ROE
44.84%
Face Value
—
EPS
$0.38
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
75
Beta
2.77
Debt / Equity
2.88
Current Ratio
6.56
Quick Ratio
6.56
Forward P/E
-7.74
Price / Sales
3.37
Enterprise Value
$101.27 M
EV / EBITDA
3.18
EV / Revenue
1.39
Rating
Strong Buy
Target Price
$5.83
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 2. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 3. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 4. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
| 5. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 6. | Cullinan Therapeutics, Inc. | $14.52 | — | $911.52 M | — | -58.85% | -44.02% | $16.74 / $5.68 | $6.79 |
| 7. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 67.33 M | 1.89 M | 1.26 M | 2.28 M | 1.47 M | — |
| Operating Profit | 56.04 M | -7.89 M | -8.43 M | -8.39 M | -7.48 M | — |
| Net Profit | 56.84 M | -6.98 M | -7.34 M | -7.18 M | -6.12 M | — |
| EPS in Rs | 0.6 | -0.07 | -0.08 | -0.08 | -0.06 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 72.76 M | 27.86 M | 33.46 M | 7.5 M |
| Operating Profit | 31.33 M | -14.89 M | -12.99 M | -35.37 M |
| Net Profit | 35.34 M | -14.23 M | -18.75 M | -33.69 M |
| EPS in Rs | 0.37 | -0.15 | -0.2 | -0.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 156.57 M | 115 M | 121.33 M | 94.18 M |
| Total Liabilities | 53.84 M | 60.08 M | 55.77 M | 16.5 M |
| Equity | 102.73 M | 54.91 M | 65.56 M | 77.68 M |
| Current Assets | 148.02 M | 106 M | 114.58 M | 86.12 M |
| Current Liabilities | 22.57 M | 20.16 M | 26.27 M | 11.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 31.63 M | 49.6 M | -35.89 M | -34.11 M |
| Investing CF | 30 M | -46.25 M | 35.51 M | 37.06 M |
| Financing CF | 10.6 M | 0.55 M | 3.08 M | 0.35 M |
| Free CF | 31.33 M | 49.49 M | -36.06 M | -34.6 M |
| Capex | -0.31 M | -0.12 M | -0.17 M | -0.49 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -16.72% | 346.12% | — | — |
| Earnings Growth % | 24.12% | 44.34% | — | — |
| Profit Margin % | -51.07% | -56.05% | -449.25% | — |
| Operating Margin % | -53.44% | -38.83% | -471.65% | — |
| Gross Margin % | 71.54% | 94.01% | 87% | — |
| EBITDA Margin % | -51.7% | -37.41% | -465.23% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.